ABSTRACT Objective Binge‐eating disorder (BED) is a serious psychological condition, often associated with trauma, as well as many critical physical and psychological consequences. Despite the availability of several evidence‐based treatments, full remission rates and long‐term recovery rates remain suboptimal.
Amaani H. Hatoum +5 more
wiley +1 more source
Thermo-related degeneration of stumpy forms of Trypanosoma brucei, the pathogen of African sleeping sickness. [PDF]
Luo JY +6 more
europepmc +1 more source
Apparent density, trypanosome infection rates and host preference of tsetse flies in the sleeping sickness endemic focus of northwestern Uganda. [PDF]
Opiro R +10 more
europepmc +1 more source
ABSTRACT Objective Around one to two in five patients prematurely disengage from eating disorder therapy. This Forum paper suggests innovative strategies to increase retention and strategies for evaluating these with patients who have eating disorders.
Tracey D. Wade, Ulrike Schmidt
wiley +1 more source
Modulation of succinyl-CoA:3-ketoacid CoA transferase activity by a single amino acid residue in acetate:succinate CoA transferase from Trypanosoma brucei, the causative agent of African sleeping sickness. [PDF]
Mochizuki K +13 more
europepmc +1 more source
Sleeping Sickness Disrupts the Sleep-Regulating Adenosine System. [PDF]
Rijo-Ferreira F +5 more
europepmc +1 more source
Free-ranging pigs identified as a multi-reservoir of Trypanosoma brucei and Trypanosoma congolense in the Vavoua area, a historical sleeping sickness focus of Côte d'Ivoire. [PDF]
Traoré BM +16 more
europepmc +1 more source
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira +12 more
wiley +1 more source
Apolipoprotein-L1 (APOL1): From Sleeping Sickness to Kidney Disease. [PDF]
Pays E.
europepmc +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source

